News

March 16, 2012 — The U.S. Food and Drug Administration (FDA) approved the premarket approval (PMA) application for the Covidien EverFlex self-expanding peripheral stent system.

March 16, 2012 - Depression increases the risk of death in patients who have a coronary stent implanted. After seven years of follow up, depressed patients were 1.5 times more likely to have died...

March 9, 2012 — Boston Scientific Corp. announced the launch of the Promus Element everolimus-eluting coronary stent system in Japan. The product was recently approved by the Ministry of Health,...

March 6, 2012 — In a development that brings advanced combination therapy treatment of peripheral artery disease (PAD) to Japanese patients for the first time, Cook Medical has received PMDA...

The U.S. Food and Drug Administration (FDA) granted the first coronary stent indication for use in patients experiencing an acute myocardial infarction (AMI), or heart attack. The Boston...

February 20, 2012 —Medtronic announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity drug-eluting stent (DES)...

February 6, 2012 — InspireMD Inc. announced positive clinical results for its MGuard stent from a controlled randomized trial conducted in Chile.

February 6, 2012 — A medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced today that the APPOSITION III...

February 1, 2012 — Boston Scientific announced the first patient use and European market launch of the Promus Element Plus everolimus-eluting coronary stent system. The first patient implant in...

January 23, 2012 – Boston Scientific Corp. said the U.S. District Court for the District of New Jersey has found all the asserted patents for a coronary stent in a lawsuit brought by Johnson...

January 18, 2012 — Boston Scientific reported nine-month clinical endpoint data from its ORION trial, demonstrating positive outcomes for the Epic self-expanding nitinol stent in patients with...

January 9, 2012 – A registry that includes every patient in Sweden having percutaneous coronary intervention (PCI) found use of newer generation drug-eluting stents (DES) is associated with lower...

January 4, 2012 – ECRI, an independent nonprofit that researches the best approaches to improving patient care, listed 10 health technology issues that hospital leaders should have on their watch...

Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug-eluting bioresorbable vascular scaffold (...

December 20, 2011 – Boston Scientific reported positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the Ion (Taxus...

December 19, 2011 – The Maryland Chapter of the American College of Cardiology (ACC) and the Society for Cardiovascular Angiography and Interventions (SCAI) reiterated their call for the state of...

Boston Scientific recently announced U.S. Food and Drug Administration (FDA) approval for the Promus Element Plus everolimus-eluting platinum chromium coronary stent system, the company's next-...

December 9, 2011 — Abbott announced Thursday the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial evaluating the safety, efficacy and performance of the...

November 22, 2011 — The thoracic aorta can pose major problems for endovascular repair when there are tortuous segments. Navigating an endograft through difficult territory can prevent its precise...

November 22, 2011 — The question remains whether patency rates for heparin-bonded polytetrafluoroethylene (PTFE) grafts are better than traditional PTFE bypasses; whether these types of grafts...